Disclosed herein are arginine salts of carbidopa and levodopa and compositionsthat include for example the argi-ninesalt of carbidopa suitable for continuous administration for treatingneurological or movement diseases or disorders such asrestless leg syndrome, Parkinson's disease, secondary parkinsonism,Huntington's disease, Parkinson's-like syndrome, PSP, MSA,ALS, Shy-Drager syndrome and conditions resulting from brain injury includingcarbon monoxide or manganese intoxication, to-getherwith administration of levodopa
